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MEN-2 Syndrome: The Value of Screening and Central Registration;
A Study of Six Kindreds in The Netherlands
H.F.A. Vasen,* A.C. Nieuwenhuijzen Kruseman, A.M.J. Moers, C.J.M. Lips,
E.K.M. Beukers, W.M. Wiersinga, and R.A. Geerdink

Since 1975, six families with the MEN-2A syndrome including 66 patients have been identified in The
Netherlands. All these patients underwent thyroidectomy for C-cell hyperplasia and/or medullary
thyroid carcinoma (MTC); eight were symptomatic (Group A), 51 were relatives ofpatients found to be
affected (Group B), and seven had had a negative screening test that became positive (Group C). To
assess the effect of screening, we compared these groups with respect to the occurrence of metastatic
MTC at thyroidectomy and the results ofthe postoperative calcitonin (CT) tests. We found that 87% of
Group A, 37% of Group B; and none of Group C had metastatic disease at surgery. The "cure rates"
in these three groups withMEN-2A, as determined by stimulated CT measurement, wasO%, 51%, and
100%, respectively. From these results it may be concluded that screening can lead to the detection of
MTC at an earlier stage which in turn could permit curative treatment and improvement of both
prognosis and life expectancy. The need for supervision of affected families by central registration to
guarantee the continuity of screening is stressed. (Henry Ford Hosp Med J 1987;35:101-3)

T

he occurrence of medullary thyroid carcinoma (MTC)
in combination with pheochromocytoma and hyperparathyroidism is a well-known hereditary syndrome (multiple
endocrine neoplasia syndrome type 2A [MEN-2A] or Sipple's
syndrome) characterized by autosomal dominant inheritance
with a high degree of penetrance but varying expression (1-4).
The only way to recognize patients with the MEN-2A
syndrome at a curable stage is periodic examination of close relatives of known patients (3,5-9). Potentially life-threatening
tumors can be identified and removed at an early stage of development (3,5-9). These advantages of periodic screening may
counterbalance the disadvantages, which include psychological
burden and violation of privacy. However, it has yet to be ascertained whether or not large-scale screening of families with
hereditary tumors meets the criteria for epidemiologic screening
programs described by Wilson and Jungner in 1968 (10). Their
most important criterion is that early treatment should improve
prognosis and offer the prospect of prolonged life expectancy.
In 1983 the Foundation for the Detection of Hereditary
Tumors was established in The Netherlands. The objectives of
this foundation include the promotion of early detection, the establishment and maintenance of a registration system, and the
guarantee of continuity of screening programs (11). Since 1983
the data on six families with the MEN-2A syndrome have been
collected in the registration center, including 66 patients with
MTC with or without pheochromocytomas. To assess the effect
of screening on the prognosis, we reviewed the data from these
families. Also the importance of central registration to guarantee the continuity of screening is discussed.
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Materials and Methods
Patients
Clinical and genetic studies were performed in six kindreds
with the MEN-2 A syndrome.
To investigate the effect of screening we divided the patients
into three groups. A, B, and C. Group A comprised patients
who came for advice because they had symptoms caused by the
MEN-2A syndrome (mainly probands). Group B was reserved
for examined relatives of patients found to be affected (call-up
group), and group C comprised patients with a previously negative screening test that became positive (converters). We compared the occurrence of metastatic MTC at thyroidectomy in
each group. Since the level of plasma calcitonin (CT) following
postoperative provocative testing is probably the most sensitive
indicator of curative thyroidectomy (9,12,13), we compared
these groups with respect to the results of such testing.
Screening program
Screening programs applied in The Netherlands include a
medical history, clinical examination, and measurement of
calcium and phosphate levels in the first-degree relatives of
patients. For the detection of MTC, the short calcium or
pentagastrin infusion test is used. CT levels were determined
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Table 1
Pattern of Expression of the MEN-2 A Syndrome
in 66 Patients

Table 2
Metastatic MTC at Diagnosis ofthe MEN-2A Syndrome:
Postoperative Calcitonin Test Results

Number of Cases
Medullary thyroid carcinoma
Medullary thyroid carcinoma -I- pheochromocytoma
Medullary thyroid carcinoma -I- pheochromocytoma
-I- hyperparathyroidism
Medullary thyroid carcinoma -I- hyperparathyroidism

43
15
6
2

by specific radioimmunoassay (4), For the detection of pheochromocytoma, 24-hour urine was collected for estimation of
adrenalin, noradrenalin, and their metabolites (4), The screening program in families with the MEN-2A syndrome starts betweenfiveand ten years of age and is continued on a yearly basis
until the age of 35. After that age less frequent screening is sufficient, ie, once every three years.
When the value of CT after stimulation is more than three
fimes the baseline value and exceeds 1,000 pg/mL, diffuse Ccell hyperplasia or MTC is likely. In patients with an abnormal
CT response in at least two separate provocative tests, surgery is
indicated. The operation of choice for MTC is total thyroidectomy with exploration of the central region of the neck. For the
surgical treatment of pheochromocytoma, the bilateral extraperitoneal laterolumbar approach is used (14).
National registry
A registration center supervised by a multihospital committee
was set up in The Netherlands in 1983 (11,15), This center is responsible for maintaining the continuity of the investigation
by periodic assessment of the screening results. Annually, a
reminder is sent to the physicians to screen the family members
at risk.
Because this project is concerned with registration of very
sensitive data on large groups of patients and their families,
much attention is paid to the protection of privacy. Persons to be
registered have several rights: the right to refuse such registration, the right of access to their own data, and even therightto
order destruction of such data. Furthermore, their data may not
be given to third parties without their permission, A supervisory
committee, composed of patients and persons with nonmedical
backgrounds, was set up. Two genetic field workers (social
workers with special training in genealogy) assist in the collection of data, the working out of pedigrees, and providing the
relatives with information on request. In addition, pamphlets
containing information about the objectives of the registration center and the syndrome itself were made available to
the relatives.

Results
Since 1983 the data of 18 families with the MEN-2 syndrome
were collected in the registration center. The data on six families
with the MEN-2A syndrome are complete, including 66 patients, 32 men and 34 women. The pattem of expression of the
disease is shown in Table 1. Six patients with MEN-2A had all
three components of the syndrome, 15 had MTC and pheochromocytoma, two had MTC and hyperparathyroidism, and
the remaining 43 had only MTC.
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Number of Cases (66)
Average Age
Metastatic MTC
Postoperative conversion of
calcitonin tests to nonnal
Basal
After stimulation

A
Symptomatic

GROUPS
B
Call-up

8
41.7
87%

51
29.4
37%

7
13.4
0%

25%
0%

70%
51%

100%
100%

C
Converter

Sixty-six patients with abnormal test results had surgery, and
thyroid abnormalities (MTC and/or C-cell hyperplasia) were
confirmed in all of these. Seven of the eight patients in Group A,
19 of the 51 patients in Group B, and none of the seven patients in
Group C had metastatic disease at the time of thyroidectomy
(Table 2). The basal CT value became normal in two of the eight
patients in Group A, 36 of the 51 patients in Group B, and in
each of the seven patients in Group C. The CT value after
provocative testing became normal in none of the eight patients
in Group A, 26 of the 51 patients in Group B, and in each of the
seven patients in Group C.

Discussion
The best way to assess the effect of pjeriodic examination in families with the MEN-2A syndrome would be to perform a
randomized controlled trial. However, because there is substantial
evidence in the literature for a favorable effect of treatment (3,5-9),
this would seem to be excluded on ethical grounds. Another way to
assess the effect of screening is to divide the patients into three
groups—a symptomatic group (group A), a call-up group (group
B). and a converter group (group C)—and compare them with
respect to the stage of the thyroid tumor at surgery and the effect
of surgery on the results of the postoperative CT test.
We found that 87% of the symptomatic group, 37% of the call-up
group, and none ofthe converters had metastatic MTC at the time of
surgery. The "cure rates" in the three groups, as determined by
stimulated CT measurement, were 0%, 51%, and 100%,
respecfively.
From thesefindingswe concluded that screening led to detection of MTC at an earlier stage, which permitted curative treatment and improvement of both prognosis and life expectancy.
However, the ulfimate value of screening must be based on the
long-term cumulafive experience with survival rates. We expect
to find that the life expectancy of prospectively screened families will not differ from that of the general population.
The responsibility for the continuity of periodic examination
is a heavy burden on the family physician or general intemist,
and experience has shown that periodic control cannot be adequately guaranteed in this way. Continuity was found to be interrupted (for example, by completion of short-term research
programs, loss of funding, departure or death of the coordinating physician, or moving away of the patients), which led to
unnecessary morbidity and mortality.
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One way to solve the practical problems involved might be to
have the administrative work organized centrally and to have the
family physician perform the main screening work. A study
group was set up in 1981 to assess the feasibility of central registration and decentralized screening of large groups of patients
with the MEN-2A syndrome and their relatives. To assure the
continuity of this project, a foundation called Foundation for the
Detection of Hereditary Tumors was established in 1983. After
three years, our experience has shown that large groups of patients and their close relatives can be handled properly by the
registration center and that the privacy of patients and relatives
can be guaranteed. Patients and physicians have been generally
enthusiastic about participating and extremely helpful with the
family studies. At present, the activities of this foundation are
limited to the MEN-2 syndromes and polyposis coli. Perhaps, if
sensitive tests and curative treatment become available, other
hereditary tumor syndromes could be included.
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